Canada: Pharmaceutical divestment forces conglomerate to revise financial outlook
A major Canadian conglomerate has announced its plans to divest its pharmaceutical company and sell the business to Kohl & Frisch Limited for between $80 million and $100 million. AmerisourceBergen Corporation will divest AmerisourceBergen Canada Corporation to the fulltime distributor in a deal that the parties expect to finalize in the year’s third fiscal quarter. ABCC represented about 2 percent of AmerisourceBergen’s total revenues; due to the transaction the company will reportedly revise its planned financial performance expectations.
Featured News
Internal Meta Documents Spotlight Regulatory Void Around Fraudulent Social Media Ads
Nov 14, 2025 by
CPI
FTC Opens Antitrust Probe Into Leading Proxy Advisory Firms
Nov 13, 2025 by
CPI
Government Has Re-Opened, But Things Are Not Yet Back to Normal
Nov 13, 2025 by
CPI
Lina Khan Reviews NYC Executive Authority Ahead of Mamdani Administration
Nov 13, 2025 by
CPI
DOJ Unveils Crypto Scam ‘Strike Force’ Targeting Criminal Networks Tied to China
Nov 13, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Entertainment & Culture
Nov 13, 2025 by
CPI
Non-Playable Character: Competition Law Enforcement in the Video Game Market
Nov 13, 2025 by
Robin S. Crauthers
Gerrymandering Sports Entertainment Product Markets
Nov 13, 2025 by
Jodi Balsam
Redistribution via Competition Policy: A Case Study of Creative Industries
Nov 13, 2025 by
Friso Bostoen
Sports Governing Bodies vs. Antitrust 0 – 4? Sport and Competition Economics Comments on the Recent Judgements of the European Court of Justice
Nov 13, 2025 by
Oliver Budzinski